320 related articles for article (PubMed ID: 30347494)
1. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
[TBL] [Abstract][Full Text] [Related]
2. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
[TBL] [Abstract][Full Text] [Related]
3. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.
Tourdot BE; Stoveken H; Trumbo D; Yeung J; Kanthi Y; Edelstein LC; Bray PF; Tall GG; Holinstat M
Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1632-1643. PubMed ID: 29748334
[TBL] [Abstract][Full Text] [Related]
4. Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking.
Norman JE; Cunningham MR; Jones ML; Walker ME; Westbury SK; Sessions RB; Mundell SJ; Mumford AD
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):952-60. PubMed ID: 26966273
[TBL] [Abstract][Full Text] [Related]
5. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.
Edelstein LC; Simon LM; Lindsay CR; Kong X; Teruel-Montoya R; Tourdot BE; Chen ES; Ma L; Coughlin S; Nieman M; Holinstat M; Shaw CA; Bray PF
Blood; 2014 Nov; 124(23):3450-8. PubMed ID: 25293779
[TBL] [Abstract][Full Text] [Related]
6. The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population.
Selvadurai MV; Riaz M; Xie S; Tonkin AM; McNeil JJ; Lacaze P; Hamilton JR
Thromb Haemost; 2022 Jul; 122(7):1130-1138. PubMed ID: 34852379
[TBL] [Abstract][Full Text] [Related]
7. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
[TBL] [Abstract][Full Text] [Related]
8. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
[TBL] [Abstract][Full Text] [Related]
9. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.
Kimmelstiel C; Stevenson R; Nguyen N; Van Doren L; Zhang P; Perkins J; Kapur NK; Weintraub A; Castaneda V; Kuliopulos A; Covic L
Thromb Res; 2019 May; 177():59-69. PubMed ID: 30851630
[TBL] [Abstract][Full Text] [Related]
10. Determination of PAR4 numbers on the surface of human platelets: no effect of the single nucleotide polymorphism rs773902.
Li S; Tarlac V; Christanto RBI; French SL; Hamilton JR
Platelets; 2021 Oct; 32(7):988-991. PubMed ID: 32819173
[TBL] [Abstract][Full Text] [Related]
11. The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes.
Denorme F; Armstrong ND; Stoller ML; Portier I; Tugolukova EA; Tanner RM; Montenont E; Bhatlekar S; Cody M; Rustad JL; Ajanel A; Tolley ND; Murray DC; Boyle JL; Nieman MT; McKenzie SE; Yost CC; Lange LA; Cushman M; Irvin MR; Bray PF; Campbell RA
J Clin Invest; 2023 Sep; 133(18):. PubMed ID: 37471144
[TBL] [Abstract][Full Text] [Related]
12. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
Holinstat M; Voss B; Bilodeau ML; McLaughlin JN; Cleator J; Hamm HE
J Biol Chem; 2006 Sep; 281(36):26665-74. PubMed ID: 16837456
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
[TBL] [Abstract][Full Text] [Related]
14. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
15. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
[TBL] [Abstract][Full Text] [Related]
16. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.
Wu CC; Wu SY; Liao CY; Teng CM; Wu YC; Kuo SC
Br J Pharmacol; 2010 Oct; 161(3):643-58. PubMed ID: 20880402
[TBL] [Abstract][Full Text] [Related]
17. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.
Kahn ML; Nakanishi-Matsui M; Shapiro MJ; Ishihara H; Coughlin SR
J Clin Invest; 1999 Mar; 103(6):879-87. PubMed ID: 10079109
[TBL] [Abstract][Full Text] [Related]
18. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.
Covic L; Gresser AL; Kuliopulos A
Biochemistry; 2000 May; 39(18):5458-67. PubMed ID: 10820018
[TBL] [Abstract][Full Text] [Related]
19. Systems biology insights into the meaning of the platelet's dual-receptor thrombin signaling.
Sveshnikova AN; Balatskiy AV; Demianova AS; Shepelyuk TO; Shakhidzhanov SS; Balatskaya MN; Pichugin AV; Ataullakhanov FI; Panteleev MA
J Thromb Haemost; 2016 Oct; 14(10):2045-2057. PubMed ID: 27513817
[TBL] [Abstract][Full Text] [Related]
20. A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant.
French SL; Thalmann C; Bray PF; Macdonald LE; Murphy AJ; Sleeman MW; Hamilton JR
Blood Adv; 2018 Jun; 2(11):1283-1293. PubMed ID: 29884748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
